|1.||Mattia, Consalvo: 1 article (09/2007)|
|2.||Coluzzi, Flaminia: 1 article (09/2007)|
|3.||Pietra, C: 1 article (09/2001)|
|4.||Voltattorni, M: 1 article (09/2001)|
|5.||Bonfante, V: 1 article (09/2001)|
|6.||Gandolfi, O: 1 article (09/2001)|
|7.||Dall'Olio, R: 1 article (09/2001)|
|8.||Poli, A: 1 article (09/2001)|
|9.||Villetti, G: 1 article (09/2001)|
|1.||Neuralgia (Stump Neuralgia)
09/01/2007 - "Given the results available to date, indantadol may have a role in the treatment of neuropathic pain if the favorable pharmacokinetic profile and efficacy of the drug are maintained in more extensive clinical trials."
09/01/2007 - "Indantadol is currently in phase II clinical trials in patients with diabetic peripheral neuropathic pain. "
01/01/2004 - "At the 1st Annual BioPartnering North America (BPN-2003) it was stated that CHF 3381 is being evaluated for the treatment of neuropathic pain. "
09/01/2007 - "Indantadol is an oral and nonselective monoamine oxidase inhibitor and NMDA antagonist that is being developed by Vernalis plc, under license from Chiesi Farmaceutici SpA, for the potential treatment of neuropathic pain. "
09/01/2007 - "Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain."
09/01/2007 - "In preclinical studies, indantadol exhibited neuroprotective effects after kainite-induced seizures, and displayed anticonvulsant and antihyperalgesic activity. "
09/01/2001 - "Following intraperitoneal or oral administrations, CHF 3381 ([n-(2-indanyl)-glycinamide hydrochloride]) protected rats against maximal electroshock (MES) test seizures. "
01/01/2004 - "Chiesi also has rights to the European patent application for use of glycinamide derivatives (including CHF 3381) in the treatment of chronic pain."
09/01/2007 - "In a human heat-capsaicin-induced pain model, indantadol at a dose of 500 mg effectively reduced the area of secondary hyperalgesia to 67%. "
09/01/2001 - "As glutamatergic pathways play a pivotal role in epilepsy, to better characterize the molecular mechanisms of action of CHF 3381, the drug effects on the binding of the excitatory amino acid antagonist [3H]-MK-801 in the presence of n-methyl-D-aspartate (NMDA), spermidine, or the combination of both ligands, were studied. "
|2.||Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor)
|4.||Excitatory Amino Acids
|5.||Dizocilpine Maleate (Dizocilpine)
|7.||Monoamine Oxidase (MAO)